compound 2q [PMID: 30986068]   Click here for help

GtoPdb Ligand ID: 10365

Synonyms: example 2-8 [US20150353552]
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Compound 2q is a PI3Kδ selective inhibitor [2]. It is one of the chemical structures that is claimed in Merck and Shanghai Chempartners' patent US20150353552A1 [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 100.19
Molecular weight 439.23
XLogP 1.65
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCn1ncc(c1C)c1nc2c(n1C)ncnc2OC1CCN(C1)C(=O)C1CCOCC1
Isomeric SMILES CCn1ncc(c1C)c1nc2c(n1C)ncnc2O[C@H]1CCN(C1)C(=O)C1CCOCC1
InChI InChI=1S/C22H29N7O3/c1-4-29-14(2)17(11-25-29)19-26-18-20(27(19)3)23-13-24-21(18)32-16-5-8-28(12-16)22(30)15-6-9-31-10-7-15/h11,13,15-16H,4-10,12H2,1-3H3/t16-/m0/s1
InChI Key FHKPLLOSJHHKNU-INIZCTEOSA-N
References
1. Achab AA, Altman MD, Deng Y, Guzi T, Kattar S, Katz JD, Methot JL, Zhou H, McGowan M, Christopher MP et al.. (2015)
Purine inhibitors of human phosphatidylinositol 3-kinase delta.
Patent number: US20150353552A1. Assignee: SHANGHAI CHEMPARTNER CO Ltd., Merck Sharp and Dohme Corp. Priority date: 16/11/2012. Publication date: 10/12/2015.
2. Methot JL, Zhou H, Kattar SD, McGowan MA, Wilson K, Garcia Y, Deng Y, Altman M, Fradera X, Lesburg C et al.. (2019)
Structure Overhaul Affords a Potent Purine PI3Kδ Inhibitor with Improved Tolerability.
J Med Chem, 62 (9): 4370-4382. [PMID:30986068]
3. Michalovich D, Nejentsev S. (2018)
Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy.
Front Immunol, 9: 369. [PMID:29535736]
4. Sriskantharajah S, Hamblin N, Worsley S, Calver AR, Hessel EM, Amour A. (2013)
Targeting phosphoinositide 3-kinase δ for the treatment of respiratory diseases.
Ann N Y Acad Sci, 1280: 35-9. [PMID:23551101]
5. Stark AK, Sriskantharajah S, Hessel EM, Okkenhaug K. (2015)
PI3K inhibitors in inflammation, autoimmunity and cancer.
Curr Opin Pharmacol, 23: 82-91. [PMID:26093105]
6. Suárez-Fueyo A, Barber DF, Martínez-Ara J, Zea-Mendoza AC, Carrera AC. (2011)
Enhanced phosphoinositide 3-kinase δ activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death.
J Immunol, 187 (5): 2376-85. [PMID:21810603]
7. Suárez-Fueyo A, Rojas JM, Cariaga AE, García E, Steiner BH, Barber DF, Puri KD, Carrera AC. (2014)
Inhibition of PI3Kδ reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse.
J Immunol, 193 (2): 544-54. [PMID:24935930]